Vivesto AB
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OASMY research report →
Price Chart
About the company
Vivesto AB, established in 1988 and headquartered in Solna, Sweden, specializes in the development, production, commercialization, and sale of pharmaceutical products within human and veterinary oncology, primarily operating in its home country. Its leading human oncology product is Apealea (paclitaxel micellar), designed for the treatment of ovarian cancer. The company's pipeline for human health also includes Docetaxel micellar, a patented formulation combining the cytotoxin docetaxel with XR-17, which is currently in Phase 1b clinical trials for prostate cancer, as well as Cantrixil for addressing ovarian cancer.
- CEO
- Erik Kinnman
- IPO
- 2015
- Employees
- 4
- HQ
- Solna, MD, SE
Get TickerSpark's AI analysis on OASMY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $20.61K
- P/E
- -5.34
- PEG
- 0.01
- P/S
- 0.00
- P/B
- 0.52
- EV/EBITDA
- -1.13
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -20.29%
- ROIC
- -20.09%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,685,401+0.0%
- Op Income
- $-34,377,000
- Net Income
- $-32,036,734+19.4%
- EPS
- $-0.48+0.0%
- OCF Growth
- +32.4%
- FCF Growth
- +7.3%
- 52W High
- $0.05
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.01
- Beta
- 1.75
- RSI (14)
- 1
- Avg Volume
- 17
No earnings-call transcripts are available for OASMY yet.
- Free Float
- 50.4%
- Shares Outstanding
- 68.69M
- Float Shares
- 34.60M
of shares held by institutions
6 13F filers
Our OASMY coverage
Recent articles, reports, and earnings notes.
No research on OASMY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OASMY report →Financial Survey: Oasmia Pharmaceutical (OTCMKTS:OASMY) versus Acrivon Therapeutics (NASDAQ:ACRV)
defenseworld.net · Apr 1
Vivesto AB (OASMY) Discusses Pipeline Advancements in Paccal Vet and Cantrixil and Strategic Capital Raise Transcript
seekingalpha.com · Nov 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.